J Avouac1, L Gossec, M Dougados. 1. René Descartes University, Medicine Faculty, and APHP Cochin Hospital, Rhumatologie B Department, Paris, France.
Abstract
OBJECTIVE: To evaluate the two generations of anti-cyclic citrullinated protein (CCP) antibodies as a diagnostic marker of rheumatoid arthritis (RA) and as a predictor of future development of RA in healthy subjects and in patients with early undifferentiated arthritis. METHODS: A systematic analysis of the literature published between 1999 and February 2006 was conducted. Data were collected on the sensitivity and specificity of the two generations of anti-CCP antibodies for diagnosing RA and predicting future development of the disease. RESULTS: Among 107 studies initially identified, 68 had interpretable data and were analysed. Diagnostic properties were assessed in 58 studies: mean (SD) sensitivity was 53 (10)% (range 41-68) and 68 (15)% (range 39-94) for anti-CCP1 and anti-CCP2, respectively; mean (SD) specificity was 96 (3)% (range 90-99) and 95 (5)% (range 81-100) for anti-CCP1 and anti-CCP2, respectively. Predictive properties were assessed in 14 studies; odds ratio (95% confidence interval) of anti-CCP1 and anti-CCP2 for the future development of RA were 20 (14 to 31) and 25 (18 to 35), respectively, among patients with early undifferentiated arthritis and 64.5 (8.5 to 489) and 28 (8 to 95), respectively, among healthy subjects. CONCLUSION: Sensitivity of the second generation of anti-CCP is close to that of rheumatoid factor, with a higher specificity, for distinguishing RA from other rheumatic diseases. Moreover, anti-CCP antibodies appear to be highly predictive of the future development of RA in both healthy subjects and patients with undifferentiated arthritis.
OBJECTIVE: To evaluate the two generations of anti-cyclic citrullinated protein (CCP) antibodies as a diagnostic marker of rheumatoid arthritis (RA) and as a predictor of future development of RA in healthy subjects and in patients with early undifferentiated arthritis. METHODS: A systematic analysis of the literature published between 1999 and February 2006 was conducted. Data were collected on the sensitivity and specificity of the two generations of anti-CCP antibodies for diagnosing RA and predicting future development of the disease. RESULTS: Among 107 studies initially identified, 68 had interpretable data and were analysed. Diagnostic properties were assessed in 58 studies: mean (SD) sensitivity was 53 (10)% (range 41-68) and 68 (15)% (range 39-94) for anti-CCP1 and anti-CCP2, respectively; mean (SD) specificity was 96 (3)% (range 90-99) and 95 (5)% (range 81-100) for anti-CCP1 and anti-CCP2, respectively. Predictive properties were assessed in 14 studies; odds ratio (95% confidence interval) of anti-CCP1 and anti-CCP2 for the future development of RA were 20 (14 to 31) and 25 (18 to 35), respectively, among patients with early undifferentiated arthritis and 64.5 (8.5 to 489) and 28 (8 to 95), respectively, among healthy subjects. CONCLUSION: Sensitivity of the second generation of anti-CCP is close to that of rheumatoid factor, with a higher specificity, for distinguishing RA from other rheumatic diseases. Moreover, anti-CCP antibodies appear to be highly predictive of the future development of RA in both healthy subjects and patients with undifferentiated arthritis.
Authors: Ulrich Sauerland; Heidemarie Becker; Matthias Seidel; Heiko Schotte; Peter Willeke; Annette Schorat; Bernhard Schlüter; Wolfram Domschke; Markus Gaubitz Journal: Ann N Y Acad Sci Date: 2005-06 Impact factor: 5.691
Authors: S Aotsuka; M Okawa-Takatsuji; K Nagatani; C Nagashio; T Kano; K Nakajima; K Ito; A Mimori Journal: Clin Exp Rheumatol Date: 2005 Jul-Aug Impact factor: 4.473
Authors: B Vander Cruyssen; I E A Hoffman; H Zmierczak; M Van den Berghe; E Kruithof; L De Rycke; H Mielants; E M Veys; D Baeten; F De Keyser Journal: Ann Rheum Dis Date: 2005-02-04 Impact factor: 19.103
Authors: M M J Nielen; A R van der Horst; D van Schaardenburg; I E van der Horst-Bruinsma; R J van de Stadt; L Aarden; B A C Dijkmans; D Hamann Journal: Ann Rheum Dis Date: 2005-01-07 Impact factor: 19.103
Authors: Belén García-Berrocal; Concepción González; Marta Pérez; José A Navajo; Isabel Moreta; Carmen Dávila; José M González-Buitrago Journal: Clin Chim Acta Date: 2005-04 Impact factor: 3.786
Authors: Bin Yang; Jun Long Zhang; Yun Ying Shi; Dong Dong Li; Jie Chen; Zhuo Chun Huang; Bei Cai; Xing Bo Song; Li Xin Li; Bin Wu Ying; Lan Lan Wang Journal: Mol Biol Rep Date: 2010-12-22 Impact factor: 2.316
Authors: Jennifer Pieper; Anatoly Dubnovitsky; Christina Gerstner; Eddie A James; Mary Rieck; Genadiy Kozhukh; Karolina Tandre; Sara Pellegrino; John A Gebe; Lars Rönnblom; Tatyana Sandalova; William W Kwok; Lars Klareskog; Jane H Buckner; Adnane Achour; Vivianne Malmström Journal: J Autoimmun Date: 2018-05-28 Impact factor: 7.094
Authors: Monika Kastner; Nancy L Wilczynski; Ann K McKibbon; Amit X Garg; R Brian Haynes Journal: J Clin Epidemiol Date: 2009-02-20 Impact factor: 6.437
Authors: Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton Journal: Clin Rheumatol Date: 2007-06-15 Impact factor: 2.980
Authors: Marja-Kaisa Koivula; Markku Heliövaara; Jarmo Ramberg; Paul Knekt; Harri Rissanen; Timo Palosuo; Juha Risteli Journal: Ann Rheum Dis Date: 2007-05-01 Impact factor: 19.103